natgillin/translations-raw huggingface dataset:
Hos patienter behandlet med doser over 30 mg/kg bør dosisreduktion i trin på 5 til 10 mg/kg overvejes, når der er opnået kontrol (fx serum-ferritinniveauer permanent under 2.500 µg/l og med en faldende tendens over tid). 
In patients treated with doses greater than 30 mg/kg, dose reductions in steps of 5 to 10 mg/kg should be considered when control has been achieved (e.g. serum ferritin levels persistently below 2,500 µg/l and showing a decreasing trend over time).
Hos patienter behandlet med doser over 21 mg/kg bør dosisreduktion i trin på 3,5 til 7 mg/kg overvejes, når der er opnået kontrol (fx serum-ferritinniveauer permanent under 2.500 µg/l og med en faldende tendens over tid). 
In patients treated with doses greater than 21 mg/kg, dose reductions in steps of 3.5 to 7 mg/kg should be considered when control has been achieved (e.g. serum ferritin levels persistently below 2,500 µg/l and showing a decreasing trend over time).
Hjælpestof, som behandleren skal være opmærksom på: Hver dispergibel tablet indeholder 136 mg lactose. 
Excipient with known effect: Each dispersible tablet contains 136 mg lactose.
I tilfælde af behandlingsskift fra filmovertrukne tabletter/granulat til dispergible tabletter, skal dosis for dispergible tabletter være 40% højere end dosis for filmovertrukne tabletter/granulat, afrundet til nærmeste hel tablet. 
In case of switching from film-coated tablets/granules to dispersible tablets, the dose of dispersible tablets should be 40% higher than the dose of film-coated tablets/granules, rounded to the nearest whole tablet.
Hjælpestof, som behandleren skal være opmærksom på: Hver dispergibel tablet indeholder 544 mg lactose. 
Excipient with known effect: Each dispersible tablet contains 544 mg lactose.
Hos patienter, der ikke er tilstrækkeligt kontrolleret ved doser på 21 mg/kg (fx serum-ferritinniveauer vedvarende over 2.500 µg/l uden at vise en aftagende udvikling over tid), bør doser op til 28 mg/kg overvejes. 
In patients not adequately controlled with doses of 21 mg/kg (e.g. serum ferritin levels persistently above 2,500 µg/l and not showing a decreasing trend over time), doses of up to 28 mg/kg may be considered.
Forhøjelserne var på > 33% i ≥ 2 på hinanden følgende tilfælde, og nogle gange over den øvre grænse af normalområdet. 
During clinical studies, increases in serum creatinine of >33% on ≥2 consecutive occasions, sometimes above the upper limit of the normal range, occurred in about 36% of patients.
Hos patienter, der ikke er tilstrækkeligt kontrolleret ved doser på 30 mg/kg (fx serum-ferritinniveauer vedvarende over 2.500 µg/l uden at vise en aftagende udvikling over tid), bør doser op til 40 mg/kg overvejes. 
In patients not adequately controlled with doses of 30 mg/kg (e.g. serum ferritin levels persistently above 2,500 µg/l and not showing a decreasing trend over time), doses of up to 40 mg/kg may be considered.
• Hvis du oplever en kombination af døsighed, smerter i den øvre højre del af maven, gulfarvning af din hud eller øjne og mørk urin (tegn på leverproblemer) 
• If you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems),
Af hensyn til miljøet må du ikke smide medicinrester i afløbet eller, toilettet eller skraldespanden. 
• Do not throw away any medicines via wastewater or household waste.
Hjælpestof, som behandleren skal være opmærksom på: Hver dispergibel tablet indeholder 272 mg lactose. 
Excipient with known effect: Each dispersible tablet contains 272 mg lactose.
Hver 3 til 6 måned bør det overvejes at øge dosis med 5-10 mg/kg, hvis patientens LIC er ≥ 7 mg Fe/g tørvægt, eller hvis serumferritin konsekvent er > 2.000 µg/l og ikke viser en nedadgående tendens, og hvis lægemidlet er veltolereret. 
After every 3 to 6 months of treatment, a dose increase in increments of 5 to 10 mg/kg should be considered if the patient's LIC is ≥7 mg Fe/g dw, or if serum ferritin is consistently >2,000 µg/l and not showing a downward trend, and the patient is tolerating the medicinal product well.
Nedsat dosis 
Starting dose
Hver 3 til 6 måned bør det overvejes at øge dosis med 3,5-7 mg/kg, hvis patientens LIC er ≥ 7 mg Fe/g tørvægt, eller hvis serumferritin konsekvent er > 2.000 µg/l og ikke viser en nedadgående tendens, og hvis lægemidlet er veltolereret. 
After every 3 to 6 months of treatment, a dose increase in increments of 3.5 to 7 mg/kg should be considered if the patient's LIC is ≥7 mg Fe/g dw, or if serum ferritin is consistently >2,000 µg/l and not showing a downward trend, and the patient is tolerating the medicinal product well.
YDRE ÆSKE TIL MULTIPAKNING (inklusive blå boks) 
OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX)
EXJADE filmovertrukne tabletter udviser højere biotilgængelighed sammenlignet med EXJADE dispergible tabletter. 
EXJADE film-coated tablets demonstrate higher bioavailability compared to the EXJADE dispersible tablet formulation.
Omtrentlige tabletdimensioner 10,7 mm x 4,2 mm. 
Approximate tablet dimensions 10.7 mm x 4.2 mm.
Ved dødelige doser i ikke-jernophobede rotter forårsagede deferasirox dannelse af mikronuclei in vivo i knoglemarven, men ikke i leveren. 
Tests of genotoxicity in vitro were negative (Ames test, chromosomal aberration test) while deferasirox caused formation of micronuclei in vivo in the bone marrow, but not liver, of non-iron-loaded rats at lethal doses.
Omtrentlige tabletdimensioner 20 mm x 5,6 mm. 
Approximate tablet dimensions 20 mm x 5.6 mm.
Allergiske reaktioner (inklusive anafylaktiske reaktioner og angioødem) 
Hypersensitivity reactions (including anaphylactic reactions and angioedema) Metabolism and nutrition disorders Not known:
I tilfælde af behandlingsskift fra dispergible tabletter til filmovertrukne tabletter, skal dosis for filmovertrukne tabletter være 30% lavere end dosis for dispergible tabletter, afrundet til nærmeste hel tablet. 
In case of switching from dispersible tablets to film-coated tablets, the dose of the film-coated tablets should be 30% lower than the dose of the dispersible tablets, rounded to the nearest whole tablet.
Omtrentlige tabletdimensioner 12 mm x 3,6 mm. 
Approximate tablet dimensions 12 mm x 3.6 mm.
≥7 mg Fe/g tørvægt eller >2.000 µg/l 
≥7 mg Fe/g dw or >2,000 µg/l
EXJADE 360 mg filmovertrukne tabletter 
EXJADE 360 mg film-coated tablets
EXJADE 125 mg dispergible tabletter Pakningerne indeholder 28, 84 eller 252 dispergible tabletter. 
EXJADE 125 mg dispersible tablets Packs containing 28, 84 or 252 dispersible tablets.
Startdosis Anbefalet startdosis for EXJADE dispergible tabletter er 20 mg/kg kropsvægt. 
Starting dose The recommended initial daily dose of EXJADE dispersible tablets is 20 mg/kg body weight.
Non-intervention post-authorisation safety study (PASS): Indehaveren af markedsføringstilladelsen skal udføre og indsende resultater af et sikkerhedsstudie gennemført i henhold til en protokol accepteret af CHMP, for at vurdere sikkerheden af deferasirox filmovertrukne tabletter i den pædiatriske population (særligt, når tabletterne knuses) 
Interventional post-authorisation safety study (PASS): In order to assess the safety of deferasirox film-coated tablets in the paediatric population (especially when the tablets are crushed), the MAH shall conduct and submit the results of a safety study conducted according to an agreed protocol.
EXJADE 250 mg dispergible tabletter Pakningerne indeholder 28, 84 eller 252 dispergible tabletter. 
EXJADE 250 mg dispersible tablets Packs containing 28, 84 or 252 dispersible tablets.
EXJADE 180 mg filmovertrukne tabletter 
EXJADE 180 mg film-coated tablets
3,5 - 7 mg/kg/dag 5-10 mg/kg/dag 
3.5 - 7 mg/kg/day 5-10 mg/kg/day
Multipakningen indeholder 30 (10 pakninger med 30) filmovertrukne tabletter. 
The multipacks contain 300 (10 packs of 30) film-coated tablets.
EXJADE indeholder lactose 
EXJADE contains lactose
EXJADE 90 mg filmovertrukne tabletter EXJADE 180 mg filmovertrukne tabletter EXJADE 360 mg filmovertrukne tabletter Deferasirox 
EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets Deferasirox
14 mg/kg/dag 20 mg/kg/dag 
14 mg/kg/day 20 mg/kg/day
Sådan skal du tage EXJADE 
How to take EXJADE
Selvom der ikke blev observeret en stigning af bivirkninger i nyrerne efter dosisoptrapning af EXJADE dispergible tabletter til doser over 30 mg/kg i kliniske studier, kan det ikke udelukkes, at der er en øget risiko for bivirkninger i nyrerne ved EXJADE dispergible tabletdoser over 30 mg/kg. 
While no increase in renal adverse events was observed after dose escalation of EXJADE dispersible tablets to doses above 30 mg/kg in clinical studies, an increased risk of renal adverse events with EXJADE dispersible tablet doses above 30 mg/kg cannot be excluded.
Selvom der ikke blev observeret en stigning af bivirkninger i nyrerne efter dosisoptrapning af EXJADE dispergible tabletter til doser over 30 mg/kg i kliniske studier, kan det ikke udelukkes, at der er en øget risiko for bivirkninger i nyrerne ved filmovertrukne tablet-doser over 21 mg/kg. 
While no increase in renal adverse events was observed after dose escalation of EXJADE dispersible tablets to doses above 30 mg/kg in clinical studies, an increased risk of renal adverse events with film-coated tablet doses above 21 mg/kg cannot be excluded.
Omtrentlige tabletdimensioner 15 mm x 4,7 mm. 
Approximate tablet dimensions 15 mm x 4.7 mm.
Hvornår skal du tage EXJADE 
When to take EXJADE
• Brug ikke lægemidlet efter den udløbsdato, der står på blister og pakningen efter EXP og 
• Do not use this medicine after the expiry date which is stated on the blister and the carton after
EXJADE anvendes til at behandle kronisk jernophobning hos patienter i alderen 6 år og derover med beta-talassæmi major forårsaget af hyppige blodtransfusioner. 
EXJADE is used to treat chronic iron overload caused by frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older.
28 mg/kg/dag 40 mg/kg/dag 
28 mg/kg/day 40 mg/kg/day
EXJADE 90 mg filmovertrukne tabletter 
EXJADE 90 mg film-coated tablets
I tillæg, producerede deferasirox dispergible tabletter i dosis op til 20 og 30 mg/kg et fald i leverjernkoncentration og serum-ferritin sammenlignelig med det opnået hos patienter med beta-talassæmi. 
In addition, in patients with liver iron concentration ≥7 mg Fe/g dw with various rare anaemias or sickle cell disease, deferasirox dispersible tablets up to 20 and 30 mg/kg produced a decrease in liver iron concentration and serum ferritin comparable to that obtained in patients with beta-thalassaemia.
Granulatet bør indtages ved at drysse hele dosen ud over blød mad, som fx yoghurt eller æblemos. 
The granules should be administered by sprinkling the full dose onto soft food, e.g. yogurt or apple sauce (pureed apple).
EXJADE 360 mg filmovertrukne tabletter Hver filmovertrukken tablet indeholder 360 mg deferasirox. 
EXJADE 360 mg film-coated tablets Each film-coated tablet contains 360 mg deferasirox.
Det kan ikke anbefales at tage deferasirox-granulat sammen med aluminiumholdige antacidapræparater, selvom deferasirox har en lavere affinitet for aluminium end for jern. 
Although deferasirox has a lower affinity for aluminium than for iron, it is not recommended to take deferasirox granules with aluminium-containing antacid preparations.
Startdosis Anbefalet startdosis for EXJADE granulat er 14 mg/kg kropsvægt. 
Starting dose The recommended initial daily dose of EXJADE granules is 14 mg/kg body weight.
EXJADE 180 mg filmovertrukne tabletter Hver filmovertrukken tablet indeholder 180 mg deferasirox. 
EXJADE 180 mg film-coated tablets Each film-coated tablet contains 180 mg deferasirox.
EXJADE 180 mg granulat EU/1/06/356/021 
EXJADE 180 mg granules EU/1/06/356/021
I tilfælde af behandlingsskift fra dispergible tabletter til granulat, skal dosis for granulatet være 30% lavere end dosis for dispergible tabletter, afrundet til nærmeste hele brev. 
In case of switching from dispersible tablets to granules, the dose of the granules should be 30% lower than the dose of the dispersible tablets, rounded to the nearest whole sachet.
Selvom der ikke blev observeret en stigning af bivirkninger i nyrerne efter dosisoptrapning af EXJADE dispergible tabletter til doser over 30 mg/kg i kliniske studier, kan det ikke udelukkes, at der er en øget risiko for bivirkninger i nyrerne ved granulat-doser over 21 mg/kg. 
While no increase in renal adverse events was observed after dose escalation of EXJADE dispersible tablets to doses above 30 mg/kg in clinical studies, an increased risk of renal adverse events with granule doses above 21 mg/kg cannot be excluded.
Startdosis Anbefalet startdosis for EXJADE filmovertrukne tabletter er 14 mg/kg kropsvægt. 
Starting dose The recommended initial daily dose of EXJADE film-coated tablets is 14 mg/kg body weight.
EXJADE 90 mg filmovertrukne tabletter Hver filmovertrukken tablet indeholder 90 mg deferasirox. 
EXJADE 90 mg film-coated tablets Each film-coated tablet contains 90 mg deferasirox.
Når dette resulterer i en daglig dosis, der er mindre end 20 mg/kg kropsvægt, skal patientens respons monitoreres. 
When this results in a daily dose less than 20 mg/kg body weight, the patient's response must be monitored and a dose increase should be considered if sufficient efficacy is not obtained (see section 5.1).
EXJADE granulat udviser højere biotilgængelighed sammenlignet med EXJADE dispergible tabletter. 
EXJADE granules demonstrate higher bioavailability compared to the EXJADE dispersible tablet formulation.
Mørkeblå, ovale, bikonvekse, filmovertrukne tabletter med skrå kanter og prægning (NVR på den ene side og 360 på den anden side). 
Dark blue, ovaloid, biconvex film-coated tablet with bevelled edges and imprints (NVR on one face and 360 on the other).
EXJADE 360 mg granulat EU/1/06/356/022 
EXJADE 360 mg granules EU/1/06/356/022
EXJADE 90 mg granulat i brev EXJADE 180 mg granulat i brev EXJADE 360 mg granulat i brev Deferasirox 
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet Deferasirox
EXJADE 180 mg filmovertrukne tabletter EU/1/06/356/014 
EXJADE 180 mg film-coated tablets EU/1/06/356/014
EXJADE 90 mg granulat EU/1/06/356/020 
EXJADE 90 mg granules EU/1/06/356/020
Natriumlaurilsulfat Silica, kolloid vandfri Magnesiumstearat 
Sodium laurilsulfate Silica, colloidal anhydrous
• At deferasirox forårsager stigninger i serum-kreatinin hos visse patienter o Nødvendigheden af at monitorere serum-kreatinin To gange før påbegyndelse af behandling Hver uge den første måned ved påbegyndelse af behandling eller efter ændring af behanding 
• That deferasirox causes rises in serum creatinine in some patients o The need to monitor serum creatinine
Mellemblå, ovale, bikonvekse, filmovertrukne tabletter med skrå kanter og prægning (NVR på den ene side og 180 på den anden side). 
Medium blue, ovaloid, biconvex film-coated tablet with bevelled edges and imprints (NVR on one face and 180 on the other).
EXJADE anvendes også til ikke-transfusionsafhængige patienter i alderen 10 år eller derover, der har fået jernophobning i forbindelse med deres talassæmi-syndromer, når deferoxamin-behandling er kontraindiceret eller utilstrækkelig. 
EXJADE is also used when deferoxamine therapy is contraindicated or inadequate to treat patients aged 10 years or older who have iron overload associated with their thalassaemia syndromes, but who are not transfusion dependent.
EXJADE 360 mg filmovertrukne tabletter EU/1/06/356/017 
EXJADE 360 mg film-coated tablets EU/1/06/356/017
EXJADE 125 mg dispergible tabletter 
EXJADE 125 mg dispersible tablets
EXJADE 90 mg filmovertrukne tabletter EU/1/06/356/011 
EXJADE 90 mg film-coated tablets EU/1/06/356/011
Exjade 180 mg granulat deferasirox 
Exjade 180 mg granules deferasirox
Exjade 360 mg granulat deferasirox 
Exjade 360 mg granules deferasirox
Ikke vurderet og ≤2.000 µg/l 
10 mg/kg/day For adults not assessed and ≤2,000 µg/l
YDRE ÆSKE TIL DELPAKNING AF MULTIPAKNING (uden blå boks) 
INTERMEDIATE CARTON OF MULTIPACK (without blue box)
EXJADE anvendes også til behandling af kronisk jernophobning, når deferoxamin ikke kan benyttes eller ikke har tilstrækkelig virkning hos patienter med beta-talassæmi major med jernophobning forårsaget af sjældne blodtransfusioner. 
EXJADE is also used to treat chronic iron overload when deferoxamine therapy is contraindicated or inadequate in patients with beta thalassaemia major with iron overload caused by infrequent blood transfusions, in patients with other types of anaemias, and in children aged 2 to 5 years.
EXJADE dispergible tabletter skal tages én gang dagligt på tom mave mindst 30 minutter før et måltid, helst på samme tidspunkt hver dag (se pkt. 
EXJADE dispersible tablets must be taken once daily on an empty stomach at least 30 minutes before food, preferably at the same time each day (see sections 4.5 and 5.2).
3,5 - 7 mg/kg/dag 5-10 mg/kg/dag Nedsat dosis 
3.5 - 7 mg/kg/day 5-10 mg/kg/day Decrease
Exjade 360 mg filmovertrukne tabletter deferasirox 
Exjade 360 mg film-coated tablets deferasirox
YDRE ÆSKE TIL MULTIPAKNING (INKLUSIV BLÅ PAKNING) 
OUTER CARTON OF MULTIPACK (including blue box)
EXJADE 500 mg dispergible tabletter 
EXJADE 500 mg dispersible tablets
Den anbefalede daglige initialdosis af EXJADE dispergible tabletter hos patienter med ikketransfusionsafhængige talassæmi-syndromer er 10 mg/kg kropsvægt. 
The recommended initial daily dose of EXJADE dispersible tablets in patients with non-transfusion-dependent thalassaemia syndromes is 10 mg/kg body weight.
Lyseblå, ovale, bikonvekse, filmovertrukne tabletter med skrå kanter og prægning (NVR på den ene side og 90 på den anden side). 
Light blue, ovaloid, biconvex film-coated tablet with bevelled edges and imprints (NVR on one face and 90 on the other).
EXJADE 360 mg granulat Hvert brev indeholder 360 mg deferasirox. 
EXJADE 360 mg granules Each sachet contains 360 mg deferasirox.
forstørrede lymfekirtler (tegn på alvorlige hudreaktioner) 
(signs of severe skin reactions),
I de tilfælde, hvor afbrydelse af behandling kan være nødvendig, kan behandlingen påbegyndes igen efter udslættet er væk. 
When interruption of treatment may be necessary, treatment may be reintroduced after resolution of the rash, at a lower dose followed by gradual dose escalation.
• Hvert brev med EXJADE 360 mg granulat indeholder 360 mg deferasirox. 
• Each sachet of EXJADE 360 mg granules contains 360 mg deferasirox.
EXJADE 180 mg granulat Hvert brev indeholder 180 mg deferasirox. 
EXJADE 180 mg granules Each sachet contains 180 mg deferasirox.
Den bløde mad med granulatet skal tages med eller uden et let måltid én gang dagligt, helst på samme tidspunkt hver dag (se pkt. 
The soft food containing the granules should be taken with or without a light meal, once a day,
Exjade 180 mg filmovertrukne tabletter deferasirox 
Exjade 180 mg film-coated tablets deferasirox
EXJADE filmovertrukne tabletter udviser højere biotilgængelighed sammenlignet med EXJADE dispergible tabletter (se pkt. 
EXJADE film-coated tablets demonstrate higher bioavailability compared to the EXJADE dispersible tablet formulation (see section 5.2).
Den anbefalede daglige initialdosis af EXJADE granulat hos patienter med ikketransfusionsafhængige talassæmi-syndromer er 7 mg/kg kropsvægt. 
The recommended initial daily dose of EXJADE granules in patients with non-transfusion-dependent thalassaemia syndromes is 7 mg/kg body weight.
EXJADE 90 mg granulat Hvert brev indeholder 90 mg deferasirox. 
EXJADE 90 mg granules Each sachet contains 90 mg deferasirox.
Den anbefalede daglige initialdosis af EXJADE filmovertrukne tabletter hos patienter med ikketransfusionsafhængige talassæmi-syndromer er 7 mg/kg kropsvægt. 
The recommended initial daily dose of EXJADE film-coated tablets in patients with non-transfusion-dependent thalassaemia syndromes is 7 mg/kg body weight.
EXJADE 125 mg dispergible tabletter Hver dispergibel tablet indeholder 125 mg deferasirox. 
EXJADE 125 mg dispersible tablets Each dispersible tablet contains 125 mg deferasirox.
Hvide til svagt gule, runde, flade tabletter med skrå kanter og prægning (NVR på den ene side og J 125 på den anden side). 
White to slightly yellow, round, flat tablets with bevelled edges and imprints (NVR on one face and J 125 on the other).
• Hvert brev med EXJADE 180 mg granulat indeholder 180 mg deferasirox. 
• Each sachet of EXJADE 180 mg granules contains 180 mg deferasirox.
EXJADE 125 mg dispergible tabletter EU/1/06/356/001 
EXJADE 125 mg dispersible tablets EU/1/06/356/001
Hvide til svagt gule, runde, flade tabletter med skrå kanter og prægning (NVR på den ene side og J 250 på den anden side). 
White to slightly yellow, round, flat tablets with bevelled edges and imprints (NVR on one face and J 250 on the other).
EXJADE 250 mg dispergible tabletter 
EXJADE 250 mg dispersible tablets
Dobbeltbestemmelse inden behandling. 
• On two occasions prior to initiation of treatment
EXJADE 90 mg granulat i brev EXJADE 180 mg granulat i brev EXJADE 360 mg granulat i brev 
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet
Exjade 90 mg filmovertrukne tabletter deferasirox 
Exjade 90 mg film-coated tablets deferasirox
Hvide til svagt gule, runde, flade tabletter med skrå kanter og prægning (NVR på den ene side og J 500 på den anden side). 
White to slightly yellow, round, flat tablets with bevelled edges and imprints (NVR on one face and J 500 on the other).
EXJADE 250 mg dispergible tabletter EU/1/06/356/003 
EXJADE 250 mg dispersible tablets EU/1/06/356/003
Hver dispergibel tablet indeholder 125 mg deferasirox. 
Each dispersible tablet contains 125 mg of deferasirox.
EXJADE 250 mg dispergible tabletter Hver dispergibel tablet indeholder 250 mg deferasirox. 
EXJADE 250 mg dispersible tablets Each dispersible tablet contains 250 mg deferasirox.
EXJADE 500 mg dispergible tabletter EU/1/06/356/005 
EXJADE 500 mg dispersible tablets EU/1/06/356/005
Enkeltpakningerne indeholder 30 breve. 
Unit packs containing 30 sachets.
• Hvert brev med EXJADE 90 mg granulat indeholder 90 mg deferasirox. 
• Each sachet of EXJADE 90 mg granules contains 90 mg deferasirox.
EXJADE 500 mg dispergible tabletter Hver dispergibel tablet indeholder 500 mg deferasirox. 
EXJADE 500 mg dispersible tablets Each dispersible tablet contains 500 mg deferasirox.
EXJADE 125 mg dispergible tabletter deferasirox 
EXJADE 125 mg dispersible tablets deferasirox
Eksempelvis kan en patient, der modtager 40 mg/kg/dag af deferoxamin fem dage om ugen (eller tilsvarende), overføres til en daglig startdosis på 20 mg/kg/dag af EXJADE dispergible tabletter. 
For patients already well managed on treatment with deferoxamine, a starting dose of EXJADE dispersible tablets that is numerically half that of the deferoxamine dose could be considered (e.g. a patient receiving 40 mg/kg/day of deferoxamine for 5 days per week (or equivalent) could be transferred to a starting daily dose of 20 mg/kg/day of EXJADE dispersible tablets).
Hver filmovertrukken tablet af EXJADE180 mg indeholder 180 mg deferasirox. 
• Each film-coated tablet of EXJADE 180 mg contains 180 mg deferasirox.
EXJADE granulat udviser højere biotilgængelighed sammenlignet med EXJADE dispergible tabletter (se pkt. 
EXJADE granules demonstrate higher bioavailability compared to the EXJADE dispersible tablet formulation (see section 5.2).
Hver filmovertrukken tablet af EXJADE360 mg indeholder 360 mg deferasirox. 
• Each film-coated tablet of EXJADE 360 mg contains 360 mg deferasirox.
EXJADE 500 mg dispergible tabletter deferasirox 
EXJADE 500 mg dispersible tablets deferasirox
Afbrydelse af behandlingen skal overvejes, hvis serum-ferritin falder konsekvent under 500 µg/l (se pkt. 
If serum ferritin falls consistently below 500 µg/l, an interruption of treatment should be considered (see section 4.4).
Hver filmovertrukken tablet af EXJADE90 mg indeholder 90 mg deferasirox. 
• Each film-coated tablet of EXJADE 90 mg contains 90 mg deferasirox.
EXJADE 250 mg dispergible tabletter deferasirox 
EXJADE 250 mg dispersible tablets deferasirox